iBio estimated 500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility
On Apr. 27, 2020, iBio announced it has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), one of 14 institutes in the Manufacturing USA Network. NIIMBL is a public-private partnership that aims to accelerate biopharmaceutical manufacturing innovations and establish an international, leading workforce to fundamentally strengthen the U.S. biopharmaceutical industry.
Tags:
Source: iBio
Credit: